Search Results - "Browne, B.C."

145 PP2A – a Novel Target for the Treatment of Lapatinib-resistant Breast Cancer by McDermott, M.S, Browne, B.C, O'Brien, N.A, Slamon, D.J, Henry, M, Meleady, P, Clynes, M, Dowling, P, Crown, J, O'Donovan, N

Get full text

143 MicroRNA-224 and −375 in Trastuzumab and Lapatinib Acquired and Innate Resistant HER2 Positive Breast Cancer Cells by Howe, K, Eustace, A.J, Souahli, S, Browne, B.C, Aherne, S, Barron, N, Walsh, N, Crown, J, O'Donovan, N

Get full text

144 Alterations in Apoptosis-related Genes in Cell Line Models of Acquired Lapatinib Resistance, Identifies Potential Therapeutic Targets for the Treatment of Lapatinib Resistant HER2-positive Breast Cancer by Eustace, A.J, Browne, B.C, McDermott, M, O'Leary, P, O'Driscoll, L, O'Brien, N, Gallagher, L, Watson, W, Crown, J, O'Donovan, N

Get full text

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells by Browne, B.C., Crown, J., Venkatesan, N., Duffy, M.J., Clynes, M., Slamon, D., O'Donovan, N.

“…Background: Although trastuzumab has improved the prognosis for HER-2-positive breast cancer patients, not all HER-2-positive breast tumours respond to…”
Get full text

Functional characterization of cancer-associated Gab1 mutations by Ortiz-Padilla, C, Gallego-Ortega, D, Browne, B C, Hochgräfe, F, Caldon, C E, Lyons, R J, Croucher, D R, Rickwood, D, Ormandy, C J, Brummer, T, Daly, R J

“…Grb2-associated binder 1 (Gab1) is a docking protein that transduces signals from a variety of tyrosine kinases, including Met and the epidermal growth factor…”
Get full text

Recent results for single-junction and tandem quantum well solar cells by Adams, J. G. J., Browne, B. C., Ballard, I. M., Connolly, J. P., Chan, N. L. A., Ioannides, A., Elder, W., Stavrinou, P. N., Barnham, K. W. J., Ekins-Daukes, N. J.

“…The band gap of the quantum well (QW) solar cell can be adapted to the incident spectral conditions by tailoring the QW depth. The single‐junction…”
Get full text

Microrna-9 and -224 In Trastuzumab Resistant HER2 Positive Breast Cancer Cells by Howe, K., Eustace, A., Souahli, S., Browne, B.C., Aherne, S., Barron, N., Walsh, N., Crown, J.P., O'Donovan, N.

Get full text

1645PD - Microrna-9 and -224 In Trastuzumab Resistant HER2 Positive Breast Cancer Cells by Howe, K., Eustace, A., Souahli, S., Browne, B.C., Aherne, S., Barron, N., Walsh, N., Crown, J.P., O'Donovan, N.

“…HER2 positive breast cancer accounts for approximately 25 % of all breast cancer cases. Trastuzumab, a humanised monoclonal antibody, is an approved…”
Get full text